Characterization of three alternative transcripts of the BRCA1 gene in patients with breast cancer and a family history of breast and/or ovarian cancer who tested negative for pathogenic mutations

International Journal of Molecular Medicine

Volumn 35, Issue 4, 2015, Pages 950-956

  Gambino, Gaetana ^a   Tancredi, Mariella ^a   Falaschi, Elisabetta ^b   Aretini, Paolo ^c   Caligo, Maria Adelaide ^a,b  

^a UNIVERSITY OF PISA   (Italy)

^b UNIVERSITY OF PISA   (Italy)

^c Fondazione Pisana per la Scienza ONLUS   (Italy)

Author keywords

Aberrant splicing; Alternative transcript; BRCA1; BRCA2; Naturally occurring

Indexed keywords

COMPLEMENTARY DNA; MESSENGER RNA; RNA ISOFORM;

3' UNTRANSLATED REGION; 5' UNTRANSLATED REGION; ADULT; AGED; ALTERNATIVE RNA SPLICING; ARTICLE; BLOOD SAMPLING; BREAST CANCER; BREAST CARCINOGENESIS; CANCER PATIENT; CLINICAL ARTICLE; CONTROLLED STUDY; FAMILY HISTORY; FEMALE; GENE MUTATION; GENETIC VARIABILITY; GENOTYPE PHENOTYPE CORRELATION; GERMLINE MUTATION; HUMAN; MIDDLE AGED; MULTIPLEX LIGATION DEPENDENT PROBE AMPLIFICATION; ONSET AGE; OPEN READING FRAME; OVARY CANCER; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; TUMOR SUPPRESSOR GENE; BREAST TUMOR; DNA SEQUENCE; EXON; GENETIC ASSOCIATION; GENETIC TRANSCRIPTION; GENETICS; HEREDITARY BREAST AND OVARIAN CANCER SYNDROME; MUTATION;

ADULT; ALTERNATIVE SPLICING; BREAST NEOPLASMS; EXONS; FEMALE; GENES, BRCA1; GENES, BRCA2; GENETIC ASSOCIATION STUDIES; HEREDITARY BREAST AND OVARIAN CANCER SYNDROME; HUMANS; MIDDLE AGED; MUTATION; RNA ISOFORMS; RNA, MESSENGER; SEQUENCE ANALYSIS, DNA; TRANSCRIPTION, GENETIC;

EID: 84923668288     PISSN: 11073756     EISSN: 1791244X     Source Type: Journal    
DOI: 10.3892/ijmm.2015.2103     Document Type: Article

References (29)

1. Miki Y, Swensen J, Shattuck-Eidens D, Futreal PA, Harshman K, Tavtigian S, Liu Q, Cochran C,Bennett LM, Ding W, et al: A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 266: 66-71, 1994.
2. Wooster R,Bignell G,Lancaster J, Swift S, Seal S, Mangion J, Collins N, Gregory S, Gumbs C and Micklem G: Identification of the breast-cancer susceptibility gene BRCA2. Nature 378: 789-792, 1995.
3. Stratton MR and Rahman N: The emerging landscape of breast cancer susceptibility. Nat Genet 40: 17-22, 2008.
4. Sanz DJ, Acedo A, Infante M, Durán M, Pérez-Cabornero L, Esteban-Cardeñosa E, Lastra E, Pagani F, Miner C and Velasco EA: A high proportion of DNA variants of BRCA1 and BRCA2 is associated with aberrant splicing in breast/ovarian cancer patients. Clin Cancer Res 16: 1957-1967, 2010.
5. Chatterjee S and Pal JK: Role of 5'- and 3'-untranslated regions of mRNAs in human diseases. Biol Cell 101: 251-262, 2009.
6. Farrugia DJ, Agarwal MK, Pankratz VS, et al: Functional assays for classification of BRCA2 variants of uncertain significance. Cancer Res 68: 3523-3531, 2008.
7. Walker LC, Whiley PJ, Couch FJ, et al: Detection of splicing aberrations caused by BRCA1 and BRCA2 sequence variants encoding missense substitutions: implications for prediction of pathogenicity. Hum Mutat 31: E1484-E1505, 2010.
8. Cartegni L, Chew SL and Krainer AR: Listening to silence and understanding non-sense: exonic mutations that affect splicing. Nat Rev Genet 3: 285-298, 2002.
9. Spurdle AB, Couch FJ, Hogervorst FB, Radice P and Sinilnikova OM: Prediction and assessment of splicing alterations: implications for clinical testing. Hum Mutat 29: 1304-1313, 2008.
10. Lu M, Conzen SD, Cole CN and Arrick BA: Characterization of functional messenger RNA splice variants of BRCA1 expressed in nonmalignant and tumor-derived breast cells. Cancer Res 56: 4578-4581, 1996.
11. Wang H, Shao N, Ding QM, Cui J, Reddy ES and Rao VN: BRCA1 proteins are transported to the nucleus in the absence of serum and splice variants BRCA1a, BRCA1b are tyrosine phosphoproteins that associate with E2F, cyclins and cyclin dependent kinases. Oncogene 15: 143-157, 1997.
12. Wilson CA, Payton MN, Elliott GS, Buaas FW, Cajulis EE, Grosshans D, Ramos L, Reese DM, Slamon DJ and Calzone FJ: Differential subcellular localization, expression and biological toxicity of BRCA1 and the splice variant BRCA1-delta11b. Oncogene 14: 1-16, 1997.
13. Orban TI and Olah E: Expression profiles of BRCA1 splice variants in asynchronous and in G1/S synchronized tumor cell lines. Biochem Biophys Res Commun 280: 32-38, 2001.
14. Orban TI and Olah E: Emerging roles of BRCA1 alternative splicing. Mol Pathol 56: 191-197, 2003.
15. Maniccia AW, Lewis C, Begum N, et al: Mitochondrial localization, ELK-1 transcriptional regulation and growth inhibitory functions of BRCA1, BRCA1a, and BRCA1b proteins. J Cell Physiol 219: 634-641, 2009.
16. Colombo M, Blok MJ, Whiley P, et al: Comprehensive annotation of splice junctions supports pervasive alternative splicing at the BRCA1 locus: a report from the ENIGMA consortium. Hum Mol Genet 23: 3666-3680, 2014.
17. Chen M and Manley JL: Mechanisms of alternative splicing regulation: insights from molecular and genomics approaches. Nat Rev Mol Cell Biol 10: 741-754, 2009.
18. Tesoriero AA, Wong EM, Jenkins MA, Hopper JL, Brown MA, Chenevix-Trench G, Spurdle AB and Southey MC; kConFab: Molecular characterization and cancer risk associated with BRCA1 and BRCA2 splice site variants identified in multiple-case breast cancer families. Hum Mutat 26: 495, 2005.
19. Antoniou AC, Durocher F, Smith P, Simard J and Easton DF; INHERIT BRCAs program members: BRCA1 and BRCA2 mutation predictions using the BOADICEA and BRCAPRO models and penetrance estimation in high-risk French-Canadian families. Breast Cancer Res 8: R3, 2006.
20. Antoniou AC, Cunningham AP, Peto J, et al: The BOADICEA model of genetic susceptibility to breast and ovarian cancers: updates and extensions. Br J Cancer 98: 1457-1466, 2008.
21. de Garibay GR, Acedo A, García-Casado Z, et al: Capillary electrophoresis analysis of conventional splicing assays: IARC analytical and clinical classification of 31BRCA2 genetic variants. Hum Mutat 35: 53-57, 2014.
22. Houdayer C, Caux-Moncoutier V, Krieger S, et al: Guidelines for analysis in molecular diagnosis derived from a set of 327 combined in silico/in vitro studies on BRCA1 and BRCA2 variants. Hum Mutat 33: 1228-1238, 2012.
23. Whiley PJ, de la Hoya M, Thomassen M, et al: Comparison of mRNA splicing assay protocols across multiple laboratories: recommendations for best practicein standardized clinical testing. Clin Chem 60: 341-352, 2014.
24. Montagna M, Santacatterina M, Torri A, Menin C, Zullato D, Chieco-Bianchi L and D'Andrea E: Identification of a 3 kb Alu-mediated BRCA1 gene rearrangement in two breast/ovarian cancer families. Oncogene 18: 4160-4165, 1999.
25. Sevcik J, Falk M, Macurek L, et al: Expression of human BRCA1Delta17-19 alternative splicing variant with a truncated BRCT domain in MCF-7 cells results in impaired assembly of DNA repair complexes and aberrant DNA damage response. Cell Signal 25: 1186-1193, 2013.
26. Mazoyer S: Genomic rearrangements in the BRCA1 and BRCA2 genes. Hum Mutat 25: 415-422, 2005.
27. Bonnet C, Krieger S, Vezain M, et al: Screening BRCA1 and BRCA2 unclassified variants for splicing mutations using reverse transcription PCR on patient RNA and an ex vivo assay based on a splicing reporter minigene. J Med Genet 45: 438-446, 2008.
28. Gutiérrez-Enríquez S, Coderch V, Masas M, Balmaña J and Diez O: The variants BRCA1 IVS6-1G>A and BRCA2 IVS15+1G>A lead to aberrant splicing of the transcripts. Breast Cancer Res Treat 117: 461-465, 2009.
29. Perrin-Vidoz L, Sinilnikova OM, Stoppa-Lyonnet D, Lenoir GM and Mazoyer S: The nonsense-mediated mRNA decay pathway triggers degradation of most BRCA1 mRNAs bearing premature termination codons. Hum Mol Genet 11: 2805-2814, 2002.